(Q42786123)

English

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

scientific article published on 3 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 November 2017

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes (English)

1 reference

Europe PubMed Central

7 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Hubert Serve

15

0 references

Steffen Koschmieder

13

object named as

Steffen Koschmieder

0 references

Carsten Müller-Tidow

21

object named as

Carsten Müller-Tidow

0 references

Torsten Haferlach

11

object named as

Torsten Haferlach

1 reference

Europe PubMed Central

7 November 2017

Claudia Haferlach

12

object named as

Claudia Haferlach

1 reference

Europe PubMed Central

7 November 2017

Gerhard Ehninger

18

object named as

Gerhard Ehninger

1 reference

Europe PubMed Central

7 November 2017

Christian Thiede

7

object named as

Christian Thiede

1 reference

Europe PubMed Central

7 November 2017

20

object named as

Thomas Büchner

1 reference

Europe PubMed Central

7 November 2017

9

object named as

Jan Braess

1 reference

Europe PubMed Central

7 November 2017

Karsten Spiekermann

10

object named as

Karsten Spiekermann

1 reference

Europe PubMed Central

7 November 2017

Maria-Cristina Sauerland

5

object named as

Maria Cristina Sauerland

1 reference

Europe PubMed Central

7 November 2017

4

object named as

Achim Heinecke

1 reference

Europe PubMed Central

7 November 2017

Bernhard Wörmann

16

object named as

Bernhard Wörmann

1 reference

Europe PubMed Central

7 November 2017

1

object named as

Utz Krug

1 reference

Europe PubMed Central

7 November 2017

Christoph Röllig

2

object named as

Christoph Röllig

1 reference

Europe PubMed Central

7 November 2017

6

object named as

Markus Schaich

1 reference

Europe PubMed Central

7 November 2017

Study Alliance Leukemia Investigators

23

object named as

Study Alliance Leukemia Investigators

1 reference

Europe PubMed Central

7 November 2017

Wolfgang Hiddemann

17

object named as

Wolfgang Hiddemann

1 reference

Europe PubMed Central

7 November 2017

Anja Koschmieder

3

object named as

Anja Koschmieder

1 reference

Europe PubMed Central

7 November 2017

author name string

Michael Kramer

8

1 reference

Europe PubMed Central

7 November 2017

Christian Rohde

14

1 reference

Europe PubMed Central

7 November 2017

Wolfgang E Berdel

19

1 reference

Europe PubMed Central

7 November 2017

German Acute Myeloid Leukaemia Cooperative Group

22

1 reference

Europe PubMed Central

7 November 2017

language of work or name

0 references

publication date

3 December 2010

1 reference

Europe PubMed Central

7 November 2017

1 reference

Europe PubMed Central

7 November 2017

376

1 reference

Europe PubMed Central

7 November 2017

9757

1 reference

Europe PubMed Central

7 November 2017

2000-2008

1 reference

Europe PubMed Central

7 November 2017

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The mechanism of C- and G-banding of chromosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962105-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)62105-8

1 reference

Europe PubMed Central

7 November 2017

1 reference

Europe PubMed Central

7 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42786123&oldid=1970513207"